PharmaCogenomics Research and Development innovator PharmaGenoma, Inc. and HairDX LLC, introduce genetic hair loss test in Japan for predicting the risk of male and female hair loss.

Today announced an exclusive agreement with Aderans Company to introduce in Tokyo the breakthrough tests starting on March 1, 2009. The HairDX test kit is listed with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as Class I medical device.

The agreement between Aderans and HairDX’s makes the sole Japanese revolutionary genetic tests and expands Aderans leadership in the hair care and medical fields.

According to Andy Goren, President and CEO of PharmaGenoma, Inc. said “PharmaGenoma is a leader in molecular dermatology and is excited to bring the latest in genetic science to Japan. We believe our partnership with Aderans will benefit millions of Japanese men and women concerned about hair loss.”

HairDX, LLC (www.hairdx.com) is a subsidiary of PharmaGenoma, Inc. Based in Irvine, CA, USA. HairDX is a molecular dermatology research and development company. HairDX markets the first genetic test for male and female hair loss.

Katsuji Tokumaru, President of Aderans Co. Ltd said “Aderans partnership with HairDX will allow people in Japan to learn their risk for hair loss early, so they can choose the best treatment to preserve their hair.”